The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
about
Pancreatic proteolytic enzyme therapy compared with gemcitabine-based chemotherapy for the treatment of pancreatic cancerCurrent therapeutic strategies for advanced pancreatic cancer: A review for cliniciansNeoadjuvant therapy for localized pancreatic cancer: guiding principlesDilemma of first line regimens in metastatic pancreatic adenocarcinomaMetastatic pancreatic cancer: Is there a light at the end of the tunnel?Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis.Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.Pancreatic adenocarcinomaA multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.Pancreatic cancer and FOLFIRINOX: a new era and new questions.Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.Emerging therapies in pancreas cancer.The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer.Modified GTX as Second-Line Chemotherapy in Advanced Pancreatic CancerBorderline resectable pancreatic cancer: on the edge of survival.Role of methylphenidate in the treatment of fatigue in advanced pancreatic cancer population.Management of advanced pancreatic cancer.Stromal expression of SPARC in pancreatic adenocarcinoma.Management options in locally advanced pancreatic cancer.Advanced stage pancreatic cancer: novel therapeutic options.Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.Optimizing initial chemotherapy for metastatic pancreatic cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.Neoadjuvant treatment for resectable pancreatic cancer: time for phase III testing?A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.Case Report: Long-Term Survival in Patients with Initial Lung-Only Metastasis from Pancreatic Adenocarcinoma.Advanced pancreatic cancer: The standard of care and new opportunities
P2860
Q24631880-97B77FA4-747A-4E86-8D53-0679EB1C506AQ26767041-0AEB83A6-220E-48FD-A71F-02CA01D1AA99Q26799428-18570B92-C6A0-4B33-B51C-A9BD7A8D6A3DQ28077147-A2369EF6-EB96-4F6A-BB8A-2833B189E677Q28082919-12AE8653-F1A7-4AD4-B1A5-A27DEBAAD4DEQ33377361-9619D241-D3C2-4813-812A-EEB7F6F433D7Q33395577-370E3BFE-01BC-48E7-9391-56C8CA680367Q33396763-9FD80A54-7F26-41A2-AEA0-9361FA91B4B6Q33427318-69D57227-6E12-44B9-8BA4-A19A55CDC53EQ33440500-F07FA7FF-F228-4A62-B80F-D59B0FB7D84CQ33560501-877A9432-3F32-4A51-9804-B69508FAD286Q34140498-D6DFC668-9F4B-4117-88EA-D73DEEDD4779Q34631279-7CFCD7EA-FFDD-4C99-BF5D-B60C7B7AE039Q35755386-1D390A35-E571-4A53-9361-588099CBCA6DQ35944817-6272C3F1-A993-4F02-8E40-414AC34FC7A2Q36097144-819BDE12-F9B8-4B8C-BC08-255267FEDD9FQ37074126-CE6062ED-0296-4983-A0B7-011DDBF2CDBEQ37197012-5A75C16B-175A-4157-BDE0-3DE34E1F0886Q37277969-768EDD4F-D7E0-4FD6-88C9-6B6C48C20603Q37308763-EBED972F-8EB6-4BC5-8CA0-0133BC8E8454Q37960190-7EBFFBBF-A136-4E77-933C-1D1B54F1FD97Q38108253-14EF01B7-17AB-4B70-9569-490DCE587C13Q38205127-750CEC48-F35C-41C6-8CD0-AFFE68A2167DQ38221089-4604916B-B671-4869-89C2-FB56708FF451Q38415959-2CCB254E-4A05-4571-8631-38F664BCC44AQ38850605-E434A392-5C25-41D4-B1CE-E869CFF21E9EQ38900432-7AB0FE73-7EDA-49B9-91E8-1B0F134AC578Q39390859-621B752F-3744-485A-A57D-F6052D8DDA96Q42408046-CB4B6501-E24B-43E6-B514-A4AD19731073Q46138064-521E51A0-5412-425B-9207-02E7E7FC6D03Q48825323-E9C9E835-AD37-4A88-85E1-D343E7AA4843Q53213858-A29106C2-AEB1-4C5C-B9F7-2229E887BBF7Q57822243-54F1E32A-005D-4F9F-B0AD-97FA191E0B7A
P2860
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
description
2007 nî lūn-bûn
@nan
2007 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@ast
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@en
type
label
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@ast
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@en
prefLabel
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@ast
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@en
P2093
P1476
The gemcitabine, docetaxel, an ...... cer: a retrospective analysis.
@en
P2093
David R Fogelman
James Strauss
John Chabot
Manisha Desai
Riolan Andrade
Robert L Fine
Stephen M Schreibman
Susan Guba
William Sherman
P2888
P304
P356
10.1007/S00280-007-0473-0
P577
2007-04-18T00:00:00Z
P5875
P6179
1042082878